# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 13G/A**

**Under the Securities Exchange Act of 1934** 

(Amendment No. 2)

## AVENUE THERAPEUTICS, INC.

				(ivallie of issue)			
				Common Stock			
				(Title of Class of Securities)			
				05360L205			
				(CUSIP Number)			
				December 31, 2020			
			(Date of	Event Which Requires Filing of this Statemer	nt)		
Check th	ne appropr	riate box	to designate the rule pursuant to which thi	s Schedule is filed:			
[	] Rule 13	3d-1(b)					
[3	K] Rule 13	3d-1(c)					
[	] Rule 13	3d-1(d)					
			over page shall be filled out for a reporting ormation which would alter the disclosures		pect to the subject class of securities, and for any subsequent		
					Section 18 of the Securities Exchange Act of 1934 ("Act") or		
otnerwis	se subject	to the lia	of that section of the Act but shall t	be subject to all other provisions of the Act (h	owever, see the Notes).		
CUSIP 1	No. 05360	0L205		13G/A	Page 2 of 8 Pages		
			PORTING PERSONS ement Inc.				
				ENTITIES ONLY			
1	1.R.S. II 20-5648		CATION NOS. OF ABOVE PERSONS (	ENTITIES ONLY)			
	CHECK	THE A	PPROPRIATE BOX IF A MEMBER OF	A GROUP (SEE INSTRUCTIONS)			
	(a) [ ]						
2	(b)[]		-				
	SEC US	SE ONLY					
3	- CAMPAGE						
	CITIZE	NSHIP (	OR PLACE OF ORGANIZATION				
4	Massacl	husetts					
			SOLE VOTING POWER				
		5	0				
	BER OF ARES		SHARED VOTING POWER				
	ICIALLY	6	0				
	/NED EACH		SOLE DISPOSITIVE POWER				
	RTING	7	0				
PERSO	N WITH:		SHARED DISPOSITIVE POWER				
		8	0				
		Ů	·				
	AGGRE	EGATE A	AMOUNT BENEFICIALLY OWNED BY	Z EACH REPORTING PERSON			
9	0						
	CHECK	IF THE	AGGREGATE AMOUNT IN ROW (9) I	EXCLUDES CERTAIN SHARES (SEE INST	TRUCTIONS)		
10	10 []						

	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)								
11									
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  12 CO								
12	CO								
CUSIP N	lo. 05360	L205		13G/A	Page 3 of 8 Pages				
	NAMES OF REPORTING PERSONS								
1	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)								
	Opaleye, L.P.								
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)								
	(a) [ ]	(a) [ ]							
2	(b)[]	D)[] EC USE ONLY							
_	SEC CS	LONEI							
3	CITIZE	NSHIP ()	R PLACE OF ORGANIZATION						
			THE TOTAL OF CHOIL ALL THE TOTAL						
4	Delawar	e	SOLE VOTING POWER						
		_	0						
	ER OF	5	SHARED VOTING POWER						
	RES CIALLY	6	0						
	NED ACH	0	SOLE DISPOSITIVE POWER						
REPO	RTING	7	0						
PERSO	WITH:	,	SHARED DISPOSITIVE POWER		_				
		8	0						
	AGGRE		MOUNT BENEFICIALLY OWNER	D BY EACH REPORTING PERSON					
9	0								
	CHECK	IF THE	AGGREGATE AMOUNT IN ROW	(9) EXCLUDES CERTAIN SHARES (SEE INSTR	UCTIONS)				
10	[]								
	PERCE	NT OF C	LASS REPRESENTED BY AMOUN	NT IN ROW (9)					
11	0%								
	TYPE C	F REPO	RTING PERSON (SEE INSTRUCTI	ONS)					
12	PN								
CUSIP N	lo. 05360	L205		13G/A	Page 4 of 8 Pages				
			ORTING PERSONS CATION NOS. OF ABOVE PERSO	NS (ENTITIES ONLY)					
1									
	James Silverman CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)								
2	(a) [ ] (b) [ ]								
	SEC US	E ONLY							
3									
CITIZENSHIP OR PLACE OF ORGANIZATION									
4	United S	States							
			SOLE VOTING POWER						
NHIME	ED OF	5	0						
SHA	ER OF RES		SHARED VOTING POWER						
	CIALLY NED	6	0						
BY E	CACH		SOLE DISPOSITIVE POWER						
REPO! PERSO!	RTING N WITH:	7	0						
			SHARED DISPOSITIVE POWER						
		8	0						
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON									

9	0								
		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)							
10	[]								
44		T OF	DF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
11	TYPE O	OF REPORTING PERSON (SEE INSTRUCTIONS)							
12	IN								
CUSIP N	No. 053601	L205	5 13G/A Page 5 of 8 Pages	Page 5 of 8 Pages					
Item 1(a	1).	Na	ame of Issuer:						
		The	he name of the issuer is Avenue Therapeutics, Inc. (the "Company").						
Item 1(b).		Address of Issuer's Principal Executive Offices:							
		The	he Company's principal executive offices are located at 1140 Avenue of the Americas, Floor 9, New York NY 10036.						
Item 2(a).		Name of Person Filing.							
		This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons" with respect to the shares of common stock of the Company:							
		<u>Opa</u>	paleye Fund						
		Opa	paleye, L.P. (the "Opaleye Fund"), a private fund formed in the state of Delaware.						
		Reporting Individual							
			Ir. James Silverman (the "Reporting Individual"), with respect to the shares of common stock held by the Opaleye Fund. Mr. Silverman is the le Investment Manager.	President of					
Item 2(b	o).	Address of Principal Business Office or, if None, Residence.							
			ne Boston Place, 26 <sup>th</sup> Floor oston, Massachusetts 02108						
Item 2(c	e).	Citizenship.							
		Citi	itizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and is incorporated herein by reference for each such Reporting Person and Incorporated herein by reference for each such Reporting Person and Incorporated herein by reference for each such Reporting Person and Incorporated herein person and Incorporated	rson.					
Item 2(d	I).	Title of Class of Securities.							
		Coı	ommon Stock, \$0.0001 par value						
Item 2(e	e).	CUSIP Number.							
		05360L205							
CUSIP N	No. 053601	L205	5 13G/A Page 6 of 8 Pages						
Item 3. 1	If This Stat	emen	ent is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:						
(a)		[]	Broker or dealer registered under Section 15 of the Exchange Act.						
(b)		[]	Bank as defined in Section 3(a)(6) of the Exchange Act.						
(c)		[]	Insurance company as defined in Section 3(a)(19) of the Exchange Act.						
(d)		[]	Investment company registered under Section 8 of the Investment Company Act.						
(e)		[]	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);						
(f)		[]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);						
(g)		[]	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);						
(h)		[]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;						
(i)		[]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;						
(j)		[]	A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);						
(k)		[]	Group, in accordance with Rule 13d-1(b)(1)(ii)(K).						
If fil	ling as a no	n-U.S	J.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:						

#### Item 4. Ownership.

(a) Amount beneficially owned:

Opaleye Management Inc. — 0 shares of common stock Opaleye, L.P. — 0 shares of common stock James Silverman — 0 shares of common stock

(b) Percent of class:

Opaleye Management Inc. — 0% Opaleye, L.P. — 0% James Silverman — 0%

CUSIP No. 05360L205 13G/A Page 7 of 8 Pages

- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote:

Opaleye Management Inc. — 0 shares Opaleye, L.P. — 0 shares James Silverman — 0 shares

(ii) Shared power to vote or to direct the vote:

Opaleye Management Inc. — 0 shares of common stock Opaleye, L.P. — 0 shares of common stock James Silverman — 0 shares of common stock

(iii) Sole power to dispose or to direct the disposition of:

Opaleye Management Inc. — 0 shares Opaleye, L.P. — 0 shares James Silverman — 0 shares

(iv) Shared power to dispose or to direct the disposition of:

Opaleye Management Inc. — 0 shares of common stock Opaleye, L.P. — 0 shares of common stock James Silverman — 0 shares of common stock

### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 05360L205 13G/A Page 8 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2021 By: /s/ James Silverman

James Silverman

Date: February 12, 2021

By: /s/ James Silverman

Name: James Silverman

Managing Member of Opaleye GP LLC, the General Partner of Opaleye, L.P.

Opaleye Management Inc.

Date: February 12, 2021

By: /s/ James Silverman
Name: James Silverman
Title: President

### JOINT FILING AGREEMENT

Title:

This Joint Filing Agreement, dated February 12, 2021, is entered into by and among Opaleye Management Inc., a Massachusetts corporation, Opaleye, L.P., a Delaware limited partnership and James Silverman, an individual (collectively referred to herein as (the "Filers"). Each of the Filers may be required to file with the U.S. Securities and Exchange Commission a statement on Schedule 13G with respect to shares of common stock, \$0.0001 par value, of Avenue Therapeutics, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one week's prior written notice or such lesser period of notice as the Filers may mutually agree.

DATED: February 12, 2021

By: /s/ James Silverman

James Silverman

Opaleye, L.P.

By: /s/ James Silverman
Name: James Silverman
Title: Managing Member of

Opaleye GP LLC, the General Partner of Opaleye, L.P.

Opaleye Management Inc.

By: /s/ James Silverman
Name: James Silverman
Title: President